According a study by the University of Texas, the Pfizer/BioNTech vaccine can still target a key mutation that has emerged in two new variants of coronavirus.

However, this is only one of many mutations that are found in the new forms of the virus.

So while the study has been welcomed, it is not being seen as definitive scientific evidence about how the vaccine will perform.

New variants have been detected in the UK and South Africa.

Both variants are spreading more quickly and this has raised questions over what level of protection vaccines can offer against them.

Covid-19 Vaccine: Israel Leads the World in Vaccination Rate

Covid-19: EU Kicks Off Mass Vaccination Campaign

Joe Biden Sets 100M Covid Vaccinations Goal for First 100 Days

The widely held view is that vaccines will still work, but researchers are on the hunt for proof.

The study focuses on a mutation called N501Y, which is emerged in both new variants.

This is thought to be important because it is in the part of the virus that makes first contact with our body’s cells and changes could make it easier to get in and cause an infection.

The researchers created two forms of the virus – one with and one without the mutation – and then bathed those viruses in blood samples taken from 20 patients that had been vaccinated in clinical trials.

The study results showed the immune systems of vaccinated patients were able to take out the new mutation.

However, the variant that emerged contain multiple mutations whose combined effects may help the virus evade the immune system.